ESPR - Esperion Therapeutics Inc.
IEX Last Trade
1.825
0.075 4.110%
Share volume: 3,136,445
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$1.75
0.08
4.29%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-02 | 2022-11-01 | 2023-02-21 | 2023-05-09 | 2023-08-01 | 2023-11-07 | 2024-02-27 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 303.980 M | 312.827 M | 247.939 M | 251.819 M | 234.626 M | 221.305 M | 205.796 M | 373.060 M | |
| Current Assets | 252.478 M | 261.785 M | 246.683 M | 250.605 M | 232.125 M | 218.227 M | 201.065 M | 365.606 M | |
| Inventories | 29.232 M | 29.545 M | 35.201 M | 39.352 M | 45.676 M | 51.435 M | 65.623 M | 73.095 M | |
| Other Current Assets | 9.557 M | 11.410 M | 10.892 M | 12.500 M | 7.180 M | 9.336 M | 4.700 M | 11.290 M | |
| Short Term Investments | 9.557 M | 11.410 M | 10.892 M | 12.500 M | 7.180 M | 9.336 M | 4.700 M | 11.290 M | |
| Total Receivables | 27.844 M | 31.489 M | 33.729 M | 36.415 M | 40.799 M | 42.623 M | 48.494 M | 54.612 M | |
| Current Cash | 185.845 M | 189.341 M | 166.861 M | 162.338 M | 138.470 M | 114.833 M | 82.248 M | 226.609 M | |
| Total Non-current Assets | 51.502 M | 51.042 M | 1.256 M | 1.214 M | 2.501 M | 3.078 M | 4.731 M | 7.454 M | |
| Property Plant Equipment | 361.000 K | 256.000 K | 164.000 K | 83.000 K | 32.000 K | 6.000 K | 0.000 | 268.000 K | |
| Other Assets | 1.085 M | 730.000 K | 1.036 M | 1.075 M | 2.413 M | 3.016 M | 4.675 M | 7.130 M | |
| Intangible Assets | 56.000 K | 56.000 K | 56.000 K | 56.000 K | 56.000 K | 56.000 K | 56.000 K | 56.000 K | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 303.980 M | 312.827 M | 247.939 M | 251.819 M | 234.626 M | 221.305 M | 205.796 M | 373.060 M | |
| Total liabilities | 595.678 M | 606.927 M | 571.717 M | 581.482 M | 606.604 M | 631.309 M | 660.790 M | 667.358 M | |
| Total current liabilities | 82.275 M | 82.345 M | 92.308 M | 95.486 M | 107.173 M | 137.708 M | 156.224 M | 164.512 M | |
| Accounts Payable | 12.832 M | 18.580 M | 23.040 M | 17.065 M | 24.558 M | 26.214 M | 31.718 M | 28.433 M | |
| Other liabilities | 211.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 22.929 M | 20.329 M | 25.144 M | 27.226 M | 23.471 M | 37.931 M | 36.381 M | 46.025 M | |
| Long term debt | 513.192 M | 524.582 M | 479.409 M | 485.996 M | 499.431 M | 493.601 M | 504.566 M | 502.846 M | |
| Other liabilities | 211.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -291.698 M | -294.100 M | -323.778 M | -329.663 M | -371.978 M | -410.004 M | -454.994 M | -294.298 M | |
| Common stock | 63.227 M | 67.806 M | 73.641 M | 78.440 M | 109.244 M | 111.869 M | 112.873 M | 169.259 M | |
| Retained earnings | -1.229 B | -1.285 B | -1.340 B | -1.402 B | -1.452 B | -1.493 B | -1.549 B | -1.488 B |